PTRF acts as an adipokine contributing to adipocyte dysfunctionality and ectopic lipid deposition by Perez-Diaz, S. et al.
ORIGINAL ARTICLE
PTRF acts as an adipokine contributing to adipocyte
dysfunctionality and ectopic lipid deposition
Sergio Perez-Diaz1 & Maria P. Garcia-Sobreviela1 & Yolanda Gonzalez-Irazabal2 & Beatriz Garcia-Rodriguez2 &
Silvia Espina1,3 & Izaskun Arenaz4 & Jose M. Arbones-Mainar1,5
Received: 5 February 2018 /Accepted: 14 May 2018
# University of Navarra 2018
Abstract
Adipose tissue (AT) expands under obesogenic conditions. Yet, when the growth exceeds a certain limit, AT becomes
dysfunctional and surplus lipids start depositing ectopically. Polymerase I and transcription release factor (PTRF) has been
proposed as a mechanism leading to a dysfunctional AT by decreasing the adipogenic potential of human adipocyte
precursors. However, whether or not PTRF can be secreted by the adipocytes into the bloodstream is not yet known.
For this work, PTRF presence was investigated in plasma. We also produced a recombinant PTRF (rPTRF) and examined
its impact on the functional interactions between the adipocyte and the hepatocyte in vitro. We demonstrated that PTRF
can be found in human plasma, and is at least in part, carried by exosomes. In vitro treatment with rPTRF increased the
hypertrophy and senescence of 3T3-L1 adipocytes. In turn, those rPTRF-treated adipocytes increased lipid accumulation
in hepatocytes. Lastly, we found a positive correlation between circulating PTRF and the concentration of PTRF in the
visceral fat depot. All these findings point toward the presence of an enlarged and dysfunctional visceral adipose tissue
which secretes PTRF. This circulating PTRF behaves as an adipokine and may partially contribute to the well-known
detrimental effects of visceral fat accumulation.
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Introduction
The adipose tissue (AT) is a plastic endocrine organ, able to
expand and contract in response to different nutritional and
metabolic cues. Under obesogenic conditions the ATexpands,
as the accumulation of triglycerides in the AT is a safe way to
store energy surplus. However, when adipose tissue growth
exceeds a certain limit, metabolic complications may develop
[22]. Some of those complications stem from the ectopic de-
position of lipids in tissues such as the muscle, liver, or the
omentum [13]. Polymerase I and transcription release factor
(PTRF) production by the adipocytes has been proposed as a
mechanism leading to a dysfunctional AT [16]. In a previous
work, we found an upregulated expression of the PTRF asso-
ciated with senescence and decreased adipogenic potential of
human adipocyte precursors [15].
PTRF is considered a intracellular protein [10]. Yet, in the
present work, we found PTRF in the bloodstream of human
subjects free of cancer and other chronic diseases, and inves-
tigated its effects on adipocytes in vitro. For this, PTRF levels
were measured in plasma, as well as both the subcutaneous
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s13105-018-0638-9) contains supplementary
material, which is available to authorized users.
* Jose M. Arbones-Mainar
jmarbones.iacs@aragon.es; https://www.adipofat.com
1 Adipocyte and Fat Biology Laboratory (AdipoFat), Unidad de
Investigación Traslacional, Instituto Aragonés de Ciencias de la
Salud (IACS), Instituto de Investigación Sanitaria (IIS) Aragón,
Hospital Universitario Miguel Servet, Isabel la Católica, 1-3,
50009 Zaragoza, Spain
2 Servicio de Bioquímica Clínica, Hospital Universitario Miguel
Servet, Zaragoza, Spain
3 Servicio de Aparato Digestivo, Hospital UniversitarioMiguel Servet,
Zaragoza, Spain
4 Biobanco del Sistema de Salud de Aragón, Instituto Aragonés de
Ciencias de la Salud (IACS), Zaragoza, Spain
5 CIBER Fisiopatología Obesidad y Nutrición (CIBERObn), Instituto
Salud Carlos III, Madrid, Spain
Journal of Physiology and Biochemistry
https://doi.org/10.1007/s13105-018-0638-9
and visceral AT of obese individuals. Moreover, we produced
a recombinant PTRF (rPTRF) and examined its impact on the
functional interactions between the adipocyte and the hepato-
cyte in vitro. These studies demonstrated that the visceral AT
produces more PTRF than the subcutaneous AT in obese in-
dividuals. This work also showed that PTRF is critical for the
adipocytes’s metabolic responses in vitro and that rPTRF-
treated adipocytes increased lipid accumulation in
hepatocytes.
Material and methods
Production of recombinant-PTRF
The full-length Mus musculus Ptrf cDNA fused with a six
histidine tail (C-His) sequence and cloned into the pReceiver
expression vector was purchased from Genecopoeia (#EX-
Mm04800-B3. Genecopoeia Rockville,MD, USA). Six nano-
grams of the expression vector were transferred by heat shock
to 25 μl (1–7 × 106 colony forming units) of competent E.coli,
BL21 (DE3)-plysS donated by Olga Abian (Institute of
Biocomputation and Physics of Complex Systems,
Universidad de Zaragoza, Zaragoza, Spain). The mixture
was incubated 30 min on ice, and then 60 s at 42 °C and
2 min back on ice. The transformed cells were maintained in
a steady shaking in a 37 °C incubator with 1 ml 2xYTmedium
for 30 min. Then, 20 μl of the medium were plated in a LB
agar supplemented with ampicillin. The plates were incubated
in a 37 °C incubator overnight. Each resultant colony was
grown in a LB ampicillin medium until reached 0.6 of optical
density measured at 600 nm. Then, the expression of the
rPTRF was induced with the Overnight ExpressTM Auto-
induction System (Novagen, Madison, WI, USA) according
to the manufacturer’s instructions.
Purification of recombinant rPTRF
Bacteria were collected by centrifugation, 10,000×g for
10 min. The pellet was resuspended with lysis buffer at
pH = 8 (50 mM NaH2PO4, 300 mM NaCl, and 10 mM imid-
azole (#A9978, Sigma-Aldrich, Madrid, Spain)) and the pro-
duced rPTRF released by sonication (10 × 15 s bursts at
100 W with 10 s on ice cooling). The lysate was centrifuged
and the cleared-supernatant loaded into nickel-conjugated
agarose column, Ni-NTA agarose (#1018244, QIAGEN,
Valencia, CA, USA). The flow-through was discarded and
the column washed to remove nonspecific bindings with wash
buffer at pH = 8 (50 mM NaH2PO4, 300 mM NaCl, and
20 mM imidazole). To obtain the rPTRF, we used a gradient
of 50 to 200 mM of imidazole-salt buffer to competitively
elute the bound polyhistidine residues. One hundred thirty-
five elution fractions of 200 μl were collected. The amount
of protein present in each fraction was examined the Bio-Rad
Protein Assay, based on the method of Bradford (#500-0006,
Bio-Rad, Hercules, CA, USA). Selected fractions were
assayed for PTRF presence using SDS-PAGE and staining
with Coomasie Blue (#161-04-06, Bio-Rad). The observed
bands were isolated with a scalpel and the protein content
identified by MALDI-TOF (Perkin–Elmer, Boston, USA).
The resultant peptides were analyzed by Mascot Data base
(Matrix Science) (Proteomics Unit, CIBA. Instituto
Aragonés de Ciencias de la Salud, Zaragoza, Spain). For sub-
sequent treatments, the eluted protein was desalted and resus-
pended in DPBS (#17-512F, Lonza, Switzerland) using
Amicon Ultra 15 filters (Merck-Millipore, Darmstadt,
Germany) following the provided protocol by the manufactur-
er. Finally the rPTRF was filtered through a 0.2-μm filter
(Thermo Fisher Scientific, San Jose, CA, USA) and frozen
until ready to use.
Cell culture, treatments, and metabolite
measurements
The 3T3-L1 cells (ATCC, Rockville, MD, USA) were main-
tained in high-glucose Dulbecco’s modified Eagle’s medium
(DMEM, Lonza) supplemented with 10% of fetal bovine se-
rum (FBS, Lonza) in normoxia conditions, 37 °C and 5% of
CO2 in humid atmosphere. Two days after confluence, the
3T3L1 were transformed to mature adipocytes as previously
described [8]. After 6–8 days post-differentiation, the mature
adipocytes were treated with the maintenance medium supple-
mented with 0, 0.1, and 0.5 μM of rPTRF or following a time
course. The content of glucose present in the culture medium
was determined following the protocol provided by Beckman
Coulter (Glucose OSR6121, Beckman Coulter, Miami, FL,
USA). The HepG2 cells (ATCC) were cultured with high-
glucose DMEM until confluence. Then, the conditioned me-
dia from the treated mature adipocytes were used to supple-
ment the HepG2 for 2 days. The lipid content was measured
by staining the cell culture with the lipophilic dye Oil Red O
[17]. Microphotographs were taken using an inverted micro-
scope (Motic AE31; Jed Pella, Redding, CA, USA).
Radioactive assays
The free fatty acids and glucose uptake, lipolysis, and de novo
lipogenesis were assayed with 0.5 nCi/μl [9,10-3H(N)]-
palmitic acid (NET043005MC; Perkin-Elmer), 15 nCi/μl
2-[1,2-3H(N)]-deoxy-D-glucose (NET549250UC, Perkin-
Elmer), and 1 nCi/μl [3H]-acetic acid (NET003005MC;
Perkin–Elmer), respectively, as described previously [8]. For
the glucose uptake, assay cells were sensitized with insulin
0.5 μM (Actrapid, Novo Nordisk, Bagsvaerd, Denmark) for
30 min and then radioisotope was added for 10 min. Finally,
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cells were washed with KRPH buffer and lysed with lysis
buffer (0.2 N NaOH, 0.1% SDS) [8].
Plasma and adipose tissue samples
Fresh plasma was donated by 17 individuals free of chronic or
acute diseases. The AT biopsies were obtained during elective
surgeries (bariatric surgery, cholecystectomy, or hernia repair)
from the abdominal subcutaneous or visceral (omental) depots
[22]. The biopsies were washed, devoid of vascular and con-
nective tissue, and subsequently stored at − 80 °C in cryopres-
ervation vials. This study was approved by our local
Institutional Review Board, the Comité de Ética de la
Investigación de la Comunidad de Aragón (CEICA), and in-
formed consent was obtained from all participants and/or their
legal guardians.
Isolation of extracellular vesicles
For the isolation of extracellular vesicles (EV) from plas-
ma, we followed the protocol provided by Théry et al. [20].
Blood samples (2 ml) were drawn from three donors free of
chronic or acute diseases using EDTA tubes (BD
Vacutainer K2E, Becton Dickinson, Plymouth, UK).
Next, the EDTA tubes underwent a series of centrifugation
steps; first, cellular debris was removed by centrifugation
(1500×g for 15 min at room temperature in a Eppendorf
5810R; Hamburg, Germany). Next, the supernatants were
centrifuged 2000×g for 30 min at 4 °C and then 12,000×g
for 45 min at 4 °C. Finally, the supernatants were ultra-
centrifuged (110,000×g for 120 min at 4 °C, Sorval WX
Ultra 100, Thermo Scientific, Asheville, NC, USA). The
pellets were resuspended in 1 ml of DPBS and washed two
times by ultra-centrifugation, 110,000×g for 60 min at
4 °C. At last, the pellets were solubilized with 100 μl of
DPBS.
Transmission electron microscopy
Twenty microliters of isolated EV were spotted onto carbon
grids. Each grid was incubated with 2% uranyl acetate
(#6159-44-0, Sigma-Aldrich) on water for 2 min in the dark.
The sections were examined under a JEOL 1010 (JEOL Ltd.,
Tokyo, Japan) transmission electron microscope. Images were
captured on the Unit of Electronic Microscopy and Biological
Systems, Faculty of Medicine, Universidad de Zaragoza,
Zaragoza, Spain.
Immunodetection of proteins
Cultured cells were lysed with 100 μl of RIPA (50 mM TRIS,
150 mM NaCl, 1% Igepal (#I8896, Sigma-Aldrich), 0.5%
sodium deoxycholate (#49647, Sigma-Aldrich), and 0.01%
de SDS (#BP-166-100, Thermo Fisher Scientific); pH = 8)
per 10 cm3 plate. A cell scraper was used to pool the cell lysate
into vials. Likewise, biopsies of AT were mechanically lysed
with RIPA buffer in glass potter elvehjem homogenizer.
Lysates were then centrifuged for 5 min (150,000 rpm,
4 °C). The pellets were discarded and the protein concentra-
tion in supernatants was measured using the Pierce BCA
Protein Assay (Thermo Fisher Scientific). Diluted plasma, cell
lysates, and EV were subjected to 10% SDS-PAGE, trans-
ferred onto PVDF membranes (#10600023, GE Healthcare
LifeScience, Germany) and subsequently blocked with 5%
skimmed milk. The immunodetection against specific targets
were carried out using the following antibodies: PTRF (sc-
133934), Caveolin-1 (sc-894), His-tag (sc-803), and Actin
(sc-1615; Santa Cruz Biotechnology, Santa Cruz, CA,
USA). The signal was increased using the appropriate sec-
ondary antibodies. Membranes were exposed to enhanced
chemiluminiscent films Novex ECL Chemiluminescent
Substrate Reagent (Thermo Fisher Scientific) and analyzed
using Image-J (National Institute of Health, Beteshda,
MD, USA).
PTRF content in plasma and adipose tissues were quanti-
fied by an antigen capture enzyme-linked immunosorbent as-
say (ELISA), using a 1:2500 dilution of the abovementioned
PTRF antibody as previously described [4].
Gene expression
Total RNA was isolated using TRizol Reagent (#T9424,
Sigma-Aldrich) and treated with DNAse (#AM2238,
Thermo Fisher Scientific) as previously described.
Subsequently, the RNA was retrotranscripted to cDNA
(#4374966, Thermo Fisher Scientific). The target genes were
amplified using specific primers and measured with
SYBRgreen I (#4472908, Thermo Fisher Scientific) in a
StepOnePlus thermocyler (Thermo Fisher Scientific). Gene
expression was calculated by the ddCT method 25 with either
actin or A-FABP as housekeeping genes.
Statistical analysis
Results are expressed as mean ± SEM. Every assay was con-
ducted at least in two independent experiments. Pairwise
group comparisons were calculated using Student’s t test for
Gaussian-distributed variables and Mann–Whitney U test for
non-Gaussian-distributed data. The p value for trend was com-
puted from the Pearson test to investigate whether or not the
responses systematically increase or decrease over the levels
of the factor variable (rPTRF dose). The statistical analysis
was performed using R version 3.1.3 (http://www.r-project.
org) and the level of significance was set at 0.05.
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Results
PTRF is present in the bloodstream and associates
with exosomes
Western blot analysis revealed that PTRF was present in human
serum (Fig. 1b). Next, we isolated exosomes from the plasma of
three individuals free of cancer or any chronic disease.
Transmission electron microscopy (TEM) imaging showed the
exosomes as a ring-shaped structure of no more than 150 nm
with the typical optical density of a lipid bilayer (Fig. 1a). To test
the presence of PTRF in these extracellular vesicles, a specific
antibodywas used for the immunodetection of PTRF byWestern
blot. Figure 1b shows the results of an autoradiographic film in
which we confirmed that this circulating PTRF was, at least
partly, carried by exosomes.
PTRF is transported into the 3T3-L1-derived
adipocytes in a time-dependent fashion
After demonstrating the presence of PTRF in plasma, wewon-
dered whether circulating PTRF may be taken up by the adi-
pocytes. We produced a recombinant murine PTRF (rPTRF)
with a histidine tail as described in material and methods and
used it to supplement cultured 3T3-L1-derived adipocytes.
Thus, 0.5 μM rPTRF was added to the culture medium and
the adipocytes were collected at 10, 20, and 40 min post-load-
ing. Figure 1c illustrates (1) that the rPTRF remained in the
Fig. 1 PTRF is a circulating protein and associates to exosomes. a
Representative transmission electron micro-photography showing the
characteristic spherical shape and the size of exosomes (arrows). b
Western blot analysis of PTRF in human plasma; P, 3T3L1-derived
adipocytes as positive control; A, and exosomes isolated from human
plasma, as described in material and methods; E, arrow indicates the
size of truncated PTRF. 3T3L1 cells were differentiated into adipocytes
and supplemented with 0.5 μM of recombinant PTRF (rPTRF) for either
0, 10, 20, and 40 min. c Immunodetection of the histidine tag (His-Tag),
PTRF, and Cav-1 in lysated adipocytes and in the rPTRF-supplemented
culture media. d Immunodetection of the His-tag in the culture medium at
the baseline and after 48 h, as well as His-tag taken up by the adipocytes
48 h post-suplementation with rPTRF. In another set of experiments
3T3L1-derived adipocytes were treated with either 0, 0.1, or 0.5 μM of
rPTRF for 48 h. e Immunodetection of PTRF, Cav-1, and A-FABP in the
whole lysated adipocytes. f Representative microphotographies of the
treated adipocytes. Arrows point to hypertrophied adipocytes. Western
blot images are the most representative of at least two independent
experiments and were cropped and obtained under same experimental
conditions
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culture medium without any degradation or proteolysis and
(2) the recombinant protein was internalized by the adipo-
cytes, as the histidine tail signal belonging to the rPTRF ap-
peared inside the cells as early as 10 min post-supplementa-
tion. This signal further increased by 80% and a 150% at 20
and 40 min, respectively, suggesting an active transport into
the cell. Likewise, rPTRF supplementation produced a con-
comitant increase in the main components of the caveolae, the
endogenous PTRF and Caveolin-1, by 150 and 300%, respec-
tively when compared to the untreated control (Fig. 1c).
rPTRF is rapidly processed inside adipocytes
Knowing the ability of adipocytes to internalize rPTRF from the
medium, we investigated whether this soluble rPTRF would
have any effect on the adipocyte’s functionality. We firstly sup-
plemented the adipocyte culture with 0.5 μM rPTRF for 8 h.
Western blot analysis of the treated adipocytes showed a 60%
decreased histidine signal and a 70% increased total PTRF levels
(endogenous + recombinant + truncated forms) after 8 h, indi-
cating some type of short-term processing of rPTRF within the
adipocyte (Supplemental Fig. 1). We next sought to investigate
some delayed consequences of rPTRF supplementation. To that
end, we treated mature adipocytes with 0, 0.1, and 0.5 μM
rPTRF for 48 h to test for some medium-term PTRF effects.
Upon rPTRF treatment, proteins and RNA were isolated from
adipocytes. Unexpectedly, adipocytes no longer signaled the his-
tidine tail after 48 h of exposure to different concentrations of
rPTRF (Fig. 1d). Concomitantly, when compared to their untreat-
ed counterparts, the adipocytes treated with 0.1 and 0.5 μM
rPTRF increased the expression of PTRF by 50% at both the
protein (Fig. 1e) and the mRNA levels (100 ± 4.8, 143 ± 3.4, and
155 ± 4.2 for the adipocytes treated with 0, 0.1, and 0.5 μM
rPTRF, respectively. p < 0.001 for both treated groups).
Simultaneous to the sustained rise in endogenous PTRF, there
was an increase of caveolin-1 by 40 and 75% in the groups
treatedwith 0.1 and 0.5μMrPTRF respectively, when compared
to untreated cells (Fig. 1e). Some adipocyte-differentiation
markers were alsomeasured, such as adipocyte fatty acid binding
protein (A-FABP) and PPARγ (Fig. 1e), which did not change
significantly upon treatment with 0.5 μM rPTRF (not shown).
However, we did observe how the treatment with rPTRF pro-
duced enlarged adipocytes (Fig. 1f).
Treatment with rPTRF modified glucose uptake
We next went on to test whether treatment with rPTRF had
any effect on adipocyte functionality. Specifically, we inves-
tigated the glucose handling by the 3T3-L1 adipocytes, as this
substrate is the main source for de novo triglyceride synthesis
in vitro. Firstly, wemeasured basal consumption of glucose by
the adipocytes. Cultures treated with 0.1 and 0.5 μM rPTRF
reduced the glucose in the medium by 15% (p = 0.014) and
20% (p < 0.001) more than the control, respectively (Fig. 2a).
We then measured the cells’ ability to take up glucose in
response to insulin upon rPTRF supplementation. For this,
we use radiolabelled 2-deoxyglucose (2DG) and insulin. In
basal conditions (no insulin present), adipocytes took up 10
and 40% (p = 0.028) more radioactive 2DG when treated with
0.1 and 0.5 μM rPTRF, respectively, compared to untreated
adipocytes. When the cells were stimulated with insulin, up-
take of 2DG was greater than basal conditions, yet indepen-
dent of rPTRF treatment (Fig. 2b). The ratios between 2DG
captured after insulin stimulation and 2DG taken up without
stimulation were calculated as surrogate marker of insulin
sensitivity. These ratios ranged from three in the control group
(the largest insulin response) to 2.2 and 1.7 in those adipocytes
treated with 0.1 and 0.5 μM of rPTRF, respectively (p = 0.034
for the difference between control and the group treated with
0.5 μM of rPTRF). Then, we measured the expression levels
of the insulin-dependent (GLUT4) and insulin-independent
(GLUT1) glucose transporters, as well as the hexokinase II
(HK2). Whereas GLUT4 mRNA levels did not change upon
rPTRF supplementation, GLUT1 increased by 40 and 90% in
the groups treated with 0.1 and 0.5 μM rPTRF, compared to
control adipocytes (p = 0.03 for the difference between both
rPTRF-treated vs control groups) (Fig. 2c). This finding might
explain, at least partially, why the expression of HK2, the
kinase responsible for phosphorylating glucose, was signifi-
cantly increased by 40% (p = 0.023) and 55% (p = 0.029) in
the groups treated with 0.1 and 0.5 μM rPTRF (Fig. 2d). All
the above would suggest a greater reliance on glucose of the
rPTRF-treated adipocytes.
Treatment with rPTRF altered de novo lipogenesis
The primary function of the adipocyte is to store lipids as
triglycerides, with glucose being the main substrate for its
synthesis by de novo lipogenesis. We did not observe dif-
ferences in the mRNA levels of the acetyl-CoA
Carboxylase α (ACACA) upon rPTRF treatment (not
shown). To test their lipogenic capacity, we loaded over-
night the adipocytes with radioactively labeled acetate.
Subsequently, the acetate incorporated into the lipid frac-
tion was measured in scintillation counter. As occurred
with ACACA expression, no changes were observed re-
garding acetate incorporation into the lipid pool (23.21 ±
2.4, 26.36 ± 2.5, 25.7 ± 2.6 CPM for the groups treated
with 0, 0.1, and 0.5 μM rPTRF, respectively). The mis-
match observed between glucose uptake and de novo syn-
thesis of captured fatty acids made us wonder about the
ultimate fate of glucose. Glucose is the energy source par
excellence and when captured by the adipocyte is rapidly
phosphorylated by hexokinases entering the glycolysis and
generating pyruvate.
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Fundamental in the metabolism of glucose and fatty
acids is the reaction carried out by the PDH by catalyzing
the glucose transformation to pyruvate. This reaction is
regulated by the pyruvate dehydrogenase kinase 4
(PDK4), which blocks the synthesis of acetyl-CoA by
phosphorylation of PDH. Compared to untreated adipo-
cytes, these treated with 0.1 and 0.5 μM rPTRF increased
40 and 125% (p = 0.044) expression of PDK4, respective-
ly (Fig. 2e). Blocking the synthesis of acetyl-CoA likely
produced an accumulation of pyruvate within the adipo-
cyte. This pyruvate might still enter the TCA bypassing
the blockade of PDK4 by carboxylation in oxalacetate by
the enzyme pyruvate carboxylase (PC). Yet, we did not
find any change in its expression levels upon rPTRF
tretament (Fig. 2f). Pyruvate may also be directed toward
glycerol from phosphoenolpyruvate. Again, this fate may
be ruled out as the expression of machinery responsible
for glyceroneogenesis was decreased in the adipocytes
treated with rPTRF. Thus, mRNA levels of phosphoenol-
pyruvate carboxykinase (PEPCK) which catalyzes the re-
action of oxalacetate to phosphonenolpyruvate and glyc-
erol 3 phosphate deshydrogrenase (G3PD), responsible
for catalyzing the transformation of dihydroxyacetone
phosphate into glycerol 3 phosphate were reduced by
60% (p = 0.0067) and 80% (p = 0.042), respectively, when
adipocytes were treated with 0.5 μM rPTRF (Fig. 2g, h).
Alternatively, pyruvate can be reduced to lactate by the
action of lactate dehydrogenase α (LDHA). We then de-
termined the expression of this enzyme and found a dra-
matic increase of 60 (p = 0.004) and 150% (p < 0.001) in
its mRNA levels when the adipocytes were treated with
0.1 and 0.5 μM rPTRF, respectively (Fig. 2i).
Treatment with rPTRF resulted in an increase
in dysfunctional adipocyte markers
Hypertrophy in the adipocytes may lead to adipocyte dys-
function [12], and this phenomenon might manifest itself
as, among others, increased cellular senescence and al-
tered adipokine secretion. We measured the p16 gene ex-
pression, involved in tissue aging, and p53, a nuclear fac-
tor involved in cell survival and senescence [5]. Although
no significant differences in pairwise comparisons were
observed in the p16 mRNA levels among treatment
groups, we did find a significant trend (p = 0.03) toward
augmented gene expression as rPTRF increased (Fig. 3a).
Likewise, p53 appeared upregulated by 150% (p = 0.01),
respectively, in adipocytes treated with 0.5 μM rPTRF
(Fig. 3b).
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Fig. 2 rPTRF increases basal glucose uptake. 3T3L1-derived adipocytes
were treated with either 0, 0.1, or 0,5 μM of rPTRF for 48 h. a
Concentration of glucose in the culture media after rPTRF treatments. b
[H3]-2DG uptake assay with (+) and without (-) 0.5 μM insulin for
10 min. mRNA levels of selected genes normalized with β-actin
expression: c Glucose receptors GLUT1 and GLUT4. d Hexokinase II.
e Pyruvate dehydrogenase kinase 4. f Pyruvate carboxylase. g
Phosphoenolpyruvate carboxykinase. h Glyceraldehyde 3-phosphate
dehydrogenase. i Lactate dehydrogenase alpha. Bars represent mean ±
SEM. p, p < 0.05 for the differences vs. fresh medium. *p < 0.05 and **p
< 0.01, differences between control (0) and treated groups (0.1 and 0.5
μM r-PTRF). #p <0.05 and ##p < 0.01 for the differences within treatment
groups (0.1 vs. 0.5 μM r-PTRF)
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Adiponectin is an important as marker of adipocyte health
status. Culture media were collected and the secreted
adiponectin was immunodetected. As Fig. 3c illustrates, the
media of adipocytes treated with 0.1 and 0.5 rPTRF contained
30 and 50% less adiponectin, respectively, than the control
group.
Adipocytes treated with rPTRF promoted lipid
accumulation in HEPG2
Considering the detrimental effects of the rPTRF and the
endocrine role the adipocytes, we hypothesized that those
dysfunctional adipocytes might result in whole body met-
abolic alterations. Ectopic deposition of fat in the liver is a
key feature in the progression of complications associated
with obesity [3]. To mimic in vitro the adipocyte-
hepatocyte axis HEPG2 hepatocytes were exposed during
48 h to the conditioned media generated by 3T3-L1 adipo-
cytes treated with the different concentrations of rPTRF.
De novo lipogenesis in the HEPG2 cells was then mea-
sured as described in material and methods. HEPG2 cells
conditioned 48 h with the medium from the adipocytes
treated with 0.1 and 0.5 μM rPTRF increased the fatty acid
synthesis by 40% (p = 0.031) and 100% (p = 0.006), re-
spectively, compared to the control group (Fig. 4a). An
increase of vacuoles inside the hepatocytes cultured with
conditioned medium from treated adipocytes was also ob-
served by microscopy. To investigate the nature of such
vacuoles, the HEPG2 cells were stained with Oil Red O.
This lipophilic dye was captured by the observed vacuoles
thus, revealing themselves as lipid droplets. The dye was
then extracted and the amount of lipids contained within
the HEPG2 cells was measured by absorbance. Media from
adipocytes treated with 0.1 and 0.5 μM rPTRF increased
lipid accumulation in HEPG2 cells by 50 and 125% (p =
0.017), respectively (Fig. 4b). To confirm the observed
results, we measured the expression of some anabolic en-
zymes. ACACA was upregulated by 45% (p = 0.010) and
77% (p = 0.002) and LDH by 8% (p = 0.4) and 40% (p =
0.003) in those HEPG2 cells treated with conditioned me-
dium from adipocytes which had been supplemented with
0.1 and 0.5 μM rPTRF, respectively (Fig. 4c). Likewise,
the lipid receptor CD36 increased its expression by 30%
(p = 0.006) in the HEPG2 cells cultured with the condi-
tioned medium of adipocytes treated with 0.5 μM rPTRF
(Fig. 4c).
Human visceral adipose tissue may be a source
of plasma PTRF
The adipose tissue releases many factors of different nature
with auto-, para-, and endocrine effects [11].The high expres-
sion of PTRF in the adipose tissue made us wonder whether
the adipose tissue might be releasing PTRF into the blood-
stream. To do this, we used plasma and adipose tissue biopsies
from obese individuals and measured PTRF by an in-house
ELISA.With a limited cohort study (n = 9male and 8 female),
we found that PTRF protein levels were two times higher in
Fig. 3 rPTRF disrupts
adipogenesis in vitro. 3T3L1 cells
were differentiated into
adipocytes and treated with either
0, 0.1, or 0,5 μM of rPTRF for
48 h. mRNA levels of a p16 and b
p53 normalized with β-actin. c
Immunodetection of adiponectin
in the culture medium after
rPTRF treatments. Bars represent
mean ± SEM. **p < 0.01,
differences between control (0)
and treated (0.1 and 0.5 μM r-
PTRF). #p < 0.05, differences
between the group 0.1 and 0.5
μM r-PTRF. Western blot images
were cropped and obtained under
same experimental conditions
PTRF acts as an adipokine contributing to adipocyte dysfunctionality and ectopic lipid deposition
the visceral (omental) than in the subcutaneous fat tissue
(Fig. 5a). Moreover, the relationship between PTRF in the
different fat depots and circulating PTRF was determined
using correlation analysis (Fig. 5b). The concentration of cir-
culating PTRFwas significantly correlated with the amount of
PTRF in the visceral adipose tissue but not with the amount of
PTRF in the subcutaneous adipose tissue. This strongly sug-
gests the important role of the visceral adipose tissue as source
of circulating PTRF.
Discussion
Obesity occurs with an expansion of the adipose tissue to store
energy surplus. Increases of adipocyte number (hyperplasia)
and adipocyte size (hypertrophy) jointly determine adipose
expansion and endogenous PTRF plays an important role in
regulating the balance between those two mechanisms [15,
16]. In this work, we showed that PTRF can also be found
in human plasma and increases adipocyte hypertrophy and
A B
C D E F
0
100
200
300
400
500
600
700
800
0 0.1 0.5
[H
3
detaroprocnietatecA]
)nim/MPC(
r-PTRF (μM)
**
*
40x
0                                                           0.1                                                     0.5                              μM r-PTRF
0
20
40
60
80
100
120
140
0 0.1 0.5
noisserpxEevitaleR
ANRm
CD36
r-PTRF (μM)
*
0
20
40
60
80
100
120
0 0.1 0.5
noisserpxEevitaleR
ANRm
PDK4
r-PTRF (μM)
0
20
40
60
80
100
120
140
160
0 0.1 0.5
noisserpxEevitaleR
ANRm
LDHα
r-PTRF (μM)
**
0
50
100
150
200
250
0 0.1 0.5
noisserpxEevitaleR
ANRm
ACACA
r-PTRF (μM)
*
*
Fig. 4 rPTRF-treated adipocyteconditioned media provokes lipid
accumulation in HEPG2 cells. HEPG2 cells were conditioned for 48 h
with the medium from 3T3L1-derived adipocytes previously treated with
0.1 and 0.5μMrPTRF for 48 h. a [H3]-acetate incorporated into the cells’
lipid fraction depending on the pretreatment of the adipocytes. b
Microphotographies of the treated HEPG2 cells. Arrows point to lipid
droplets within the cells. mRNA levels with β-actin of c acetyl-CoA
carboxylase alpha, d pyruvate dehydrogenase kinase 4, e lactate
dehydrogenase alpha, and f cluster of differentiation 36 in the HEPG2
cells cultured with conditioned adipocyte medium. Values are
representative of at least two independent experiments. Bars represent
mean ± SEM. *p < 0.05 and **p < 0.01, differences between control (0)
and treated (0.1 and 0.5 μM r-PTRF) cell lines
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Fig. 5 Circulating PTRF correlates with PTRF levels in visceral adipose
tissue. PTRF levels were determined in plasma and adipose depots of
obese individuals using an in-house ELISA as described in material and
methods. a Quantitative detection of PTRF in the subcutaneous (SAT)
and visceral (VAT) adipose tissues. Correlation analyses of circulating
PTRF and PTRF levels in the visceral (b) and the subcutaneous (c)
adipose tissues. r, Pearson correlation coefficient
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senescence in vitro. Furthermore, we demonstrated for the
first time differences in PTRF production between subcutane-
ous and visceral fat tissue in obese individuals and also we
found a positive correlation between circulating PTRF and the
concentration of PTRF in the visceral fat depot.
We, and others, have defined some mechanisms whereby
PTRF plays a crucial role in impeding a healthy adipose tissue
expansion [1, 15, 16]. For this work, we set out to test whether
PTRTmight have some endocrine/paracrine influence beyond
its effect as endogenous factor. Some studies have already
reported the presence of extracellular PTRF in viral capsids
[9] and in bladder cancer exosomas [24].Yet, this is the first
report showing that PTRF circulates in the blood of individ-
uals free of cancer or any viral disease. Moreover, we also
proved that PTRF associated with exosomes. To investigate
exogenous PTRF effects on the adipose tissue, we treated
adipocytes in vitro with a recombinant murine PTRF
(rPTRF). The uptake of rPTRF was sustained over time until
its saturation at 1 h post-loading. These phenomena suggest
the existence of some system of internalization for rPTRF via
facilitated or active transport. PTRF has some domains sus-
ceptible to recognize other lipid membranes [2] and thus inte-
grate into caveolae in presence of cholesterol and caveolin-1
[25], although the existence of some yet unknown specific
PTRF receptor in the adipocyte cannot be ruled out either.
Alternatively, rPTRF transported in exosomes may be also
shipped into other target cells using some exosome-specific
mechanisms ranging from macro-pinocytosis to membrane
fusion, through dependent and independent endocytosis of
clathrins. Further investigation is needed as targeting PTRF-
internalization mechanism(s) may open new avenues in the
treatment of metabolic diseases using cell therapy.
rPTRF’s histidine tail gradually disappeared after 48 h.
This progressive degradation led us to assume that, once in-
ternalized, rPTRF reached the endosome system for its degra-
dation or recycling. We posit that both processes occur simul-
taneously. PTRF contains some PEST domains associated
with proteins that have a short intracellular half-life [2] which
some authors have dated in 6 h [21]. Accordingly, we iden-
tified by Western blot some truncated forms of PTRF of
unknown function (Fig. 1b), likely generated by specific
proteolysis. We also detected an increase in the native form
of total PTRF suggesting that PTRF recycling is also
playing a role in rPTRF processing. This would explain
the increase of PTRF and caveolin-1 over time in adipo-
cytes treated with rPTRF. Muller et al. reported that adipo-
cytes can enlarge when treated with certain EV [14] which
triggered the expression of some adipogenic genes among
which are regulators of caveola expression [19]. We hy-
pothesize that the larger size of the adipocytes treated with
rPTRF may be explained by an increased number of cave-
olae, thus allowing the adipocyte to have a membrane res-
ervoir to rapidly increase cell surface.
rPTRF-treated adipocytes mainly relied on glucose at basal
conditions, as we learned from the rapid reduction of glucose
from the culture medium, the augmented incorporation of
2DG, as well as the increased expression of HK2, whose
over-expression facilitates the assimilation of glucose [7,
23]. Nevertheless, this increased glucose uptake did not trans-
late into an enhanced TG synthesis, increasing only 10% de
novo fatty acid synthesis. When we investigated the fate of
this glucose, we found a rPTRF-associated increase in the
gene expression of PDK4, a metabolic check-point which pre-
vents pyruvate from entering the tricarboxylic acid (TCA)
cycle. The adipocyte has then several alternatives for the ac-
cumulated pyruvate. Oxaloacetate can be produced from py-
ruvate through pyruvate carboxylase (PC) and then catalyzed
by PEPCK to generate phosphoenolpyruvate as initial steps of
glyceroneogenesis (GNG). Yet, we did not find any effect of
rPTRF on PC mRNA levels, and when we measured the ex-
pression of two key enzymes of the GNG, both PEPCK and
G3PDH were decreased in the group treated with the highest
concentration of rPTRF. Interestingly, we did find an upregu-
lated expression of LDHA in those cells treated with rPTRF.
Although lactate production is classically associated with an-
aerobic metabolism, its production has been also observed in
oxygenated environments rich in glucose [18]. Therefore, the
rPTRF-specific increase in glucose uptake resulted in an over-
expression of LDHA. Our results are in line with previous
reports in which the increase of important caveolar members
led to an increased glucose uptake, adipocyte size, and lactate
production [6].
In our in vitro liver-adipose tissue model, those HEPG2
supplemented with the conditioned medium from rPTRF-
treated adipocytes increased the expression of ACACA
and showed augmented lipid droplets within the hepato-
cytes. Likewise, the HEPG2 treated with this conditioned
medium from adipocytes overexpressed the lipid transport-
er CD36. Herein, we show for the first time how exoge-
nous PTRF produced dysfunctional adipocytes which, in
turn, provoked lipid accumulation in a hepatocyte model in
vitro. Dysfunctional adipose tissue and fat accumulation in
the liver are common features which lead to metabolic
syndrome and diabetes. Accordingly, once we proved that
PTRF is a circulating protein with endocrine effects, we
wondered where this circulating PTRF might be coming
from. We found that PTRF levels were 100% higher in
visceral than in subcutaneous fat tissue and also found a
positive association between the levels of PTRF in visceral
adipose and plasma. Indeed, PTRF levels in the visceral de-
pot accounted for an ~ 30% of the variation of circulating
PTRF in obese individuals. All these findings point toward
the presence of an enlarged and dysfunctional visceral adipose
tissue which secretes PTRF into the circulation. This circulat-
ing PTRF may partially contribute to the well-known detri-
mental effects of visceral fat accumulation.
PTRF acts as an adipokine contributing to adipocyte dysfunctionality and ectopic lipid deposition
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